DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Thomas Triomphe - 1 BioNTech - 1 Ludwig Burger - 1 Elaine Hardcastle - 1
Top related locs:
Top related orgs:
Sanofi - 1 Pfizer - 1 COVID - 1 GSK - 1 Merck & Co - 1 Thomson - 1

Search resuls for: "Thomas Triomphe"


2 mentions found


☆ Sanofi says it's back to the drawing board on mRNA flu vaccines
  + stars: | 2023-06-29 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
Both A and B viruses are responsible for seasonal flu epidemics each year and currently available flu shots work against both strains. "To succeed in mRNA flu, you need the next generation of mRNA technology, which is exactly what we are working on," Thomas Triomphe, head of vaccines at Sanofi, told Reuters. Pfizer (PFE.N) last year started a large late-stage trial testing an mRNA-based flu vaccine candidate. Sanofi, which is among the top four global vaccines makers by sales, trailing GSK (GSK.L), Merck & Co (MRK.N) and Pfizer (PFE.N), has a broad vaccines offering, including flu, childhood shots and travel vaccines. The French company's vaccine sales accounted for 7.2 billion euros ($7.85 billion) of 43 billion euros in group sales last year.
Persons: Thomas Triomphe, BioNTech, Ludwig Burger, Elaine Hardcastle Organizations: Sanofi, Reuters, Pfizer, COVID, GSK, Merck & Co, Thomson
☆ Sanofi, GSK score late win with EU COVID booster approval
  + stars: | 2022-11-10 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
The shot is based on lab-made viral proteins provided by Sanofi and an adjuvant ingredient from GSK that increases the immune response. Adapting the older protein technology chosen by Sanofi and GSK to a new virus variant requires several months longer than under the mRNA approach, which saw a breakthrough during the pandemic. Work on the shot by Sanofi and GSK, two of the world's largest vaccine makers by sales, was delayed repeatedly. The partners later pivoted to targeting the Beta variant, requiring months in additional development time. While the shot tested at the time was bivalent - meaning it was based both on original Wuhan strain of the virus and Beta - Sanofi and GSK later focused on a monovalent shot based on Beta only.
0 next >>
Total: 2